A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten
compared with placebo in participants with symptomatic non-obstructive hypertrophic
cardiomyopathy (nHCM).